For decades, Europa has been the optimistic counterpoint to a lonely solar system, a small icy world that seemed to tick ...

A multi-disciplinary team of researchers linked atomic-scale features to efficient heat-to-electricity conversion, offering ...

Despite generating over $75B annually, specialty crops face rising costs, weak prices and limited safety nets. Case studies ...

The transaction involved 65 residential properties across two separate South Wales portfolios acquired through a ...

Scientists may have cracked the case of whether a seven-million-year-old fossil could walk upright. A new study found strong ...

SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. 10 stocks we like better than Structure Therapeutics › Monday ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

Dec 8 (Reuters) - Structure Therapeutics (GPCR.O), opens new tab said on Monday its obesity pill showed weight loss of up to 11.3% after 36 weeks of treatment in a mid-stage study, driving the company ...

A pill from Structure Therapeutics Inc. helped patients lose roughly as much weight as a rival treatment from Eli Lilly & Co., giving the startup an edge as it seeks to break into the highly ...